Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study-Reference-Cited by-同舟云学术

Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study

Published:2022-12-17 Issue:2 Volume:39 Page:299-306
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Waters Heidi C.¹,Touya Maelys²,Wee Soon Nan³,Ng Michelle³,Thadani Simran³,Surendran Subina³,Rentería Miguel³,Rush A. John⁴⁵⁶,Patel Rashmi³⁷,Sarkar Joydeep³,Fitzgerald Heather M.²,Han Xue¹

Affiliation:

1. Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, USA

2. Lundbeck, Deerfield, IL, USA

3. Holmusk Technologies Inc, New York, NY, USA

4. Department of Psychiatry, Duke-National University of Singapore (NUS), Singapore

5. Duke University School of Medicine, Durham, NC, USA

6. Texas Tech Health Sciences Center, Odessa, TX, USA

7. King’s College London, London, UK

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2148461

Reference35 articles.

1. National Institutes of Mental Health. Schizophrenia. Bethesda (MD): National Institutes of Health; 2022. Available from: NIMH » Schizophrenia (nih.gov.)

2. American Psychiatric Society. Diagnostic and statistical manual of mental disorders. Washington (DC): American Psychiatric Association; 2013. Available from: https://cdn.websiteeditor.net/30f11123991548a0af708722d458e476/files/uploaded/DSM%2520V.pdf

3. Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions – III

4. Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia

5. Bipolar disorders